Interestingly, Class I PI3K and AKT inhibition has also been shown to increase PI3K Class III hVsp34-SGK3 signaling in breast cancer cells, which can substitute for AKT by phosphorylating TSC2 to activate mTORC1 [148]. Here, PIK3CD is linked to breast cancer.